REVENIO GROUP OYJ |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.73 EUR | +1.17% |
|
+2.93% | -1.62% |
| Apr. 25 | Transcript : Revenio Group Oyj, Q1 2024 Earnings Call, Apr 25, 2024 | |
| Apr. 24 | Revenio Group Oyj Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Sales forecast by analysts have been recently revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 33.52 and 26.17 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -1.62% | 757M | - | ||
| -15.43% | 18.88B | A | ||
| -42.33% | 2.84B | C+ | ||
| +17.00% | 1.85B | - | - | |
| -0.51% | 1.66B | - | ||
| +27.23% | 1.26B | B+ | ||
| -13.90% | 989M | - | ||
| -21.76% | 896M | - | C- | |
| -23.95% | 637M | B+ | ||
| +6.13% | 500M | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- REG1V Stock
- Ratings Revenio Group Oyj